# The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase I Clinical Study

> **NCT06770296** · PHASE1 · RECRUITING · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 200 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Pyrotinib low dose group
- **DRUG:** Pyrotinib normal dose group

## Key facts

- **NCT ID:** NCT06770296
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-01
- **Primary completion:** 2026-11-01
- **Final completion:** 2028-11-01
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2025-01-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06770296

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06770296, "The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase I Clinical Study". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06770296. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*